Bemcentinib, Keytruda combo hits endpoints in mid-stage NSCLC trial

7th November 2019 Uncategorised 0

Bemcentinib, formerly known as BGB324, is a potentially first-in-class selective AXL inhibitor.

More: Bemcentinib, Keytruda combo hits endpoints in mid-stage NSCLC trial
Source: News